Table 1 Summary of the relationship between EGFR copy number, expression, and the patients' clinical-pathological characteristics

Age(years)

≤35

5/10.9

4/4.3

0.265^c

23/92.0

107/93.9

1.000^c

>35

41/89.1

89/95.7

2/8.0

7/6.1

Lymph node metastasis

Positive

23/50

49/52.7

0.765^a

16/64.0

56/49.1

0.178^a

Negative

23/50

44/47.3

9/36.0

58/50.9

Stage

0

0/0

2/2.2

0.748^{a, $}

1/4.0

2/1.8

0.450^{a, $}

I

10/21.7

18/19.4

6/24.0

21/18.4

II

25/54.3

53/57

11/44.0

67/58.8

III

10/21.7

20/21.5

7/28.0

22/20.2

IV

1/2.2

0/0

0/0

1/0.9

Tumor type

DCIS

0/0

3/3.2

0.551^{b, &}

1/4.0

2/1.8

1.000^{c, &}

LCIS

0/0

0/0

0/0

0/0

IDC

44/95.7

83/89.2

23/92.0

104/91.2

ILC

0/0

3/3.2

0/0

3/2.6

Other

2/4.3

4/4.3

1/4.0

5/4.4

ER

Positive

33/71.7

72/77.4

0.464^a

13/52.0

92/80.7

0.002^a

Negative

13/28.3

21/22.6

12/48.0

22/19.3

PR

Positive

27/58.7

54/58.1

0.943^a

5/20.0

76/66.7

0.000^a

Negative

19/41.3

39/41.9

20/80.0

38/33.3

HER2

Positive

9/19.6

16/17.2

0.733^a

5/20.0

29/25.4

0.567^a

Negative

37/80.4

77/82.8

20/80.0

85/74.6

Ki-67 (%)

< 14

7/15.2

35/37.6

0.007^a

17/68.0

67/58.8

0.393^a

> 16

39/84.8

58/62.4

8/32.0

47/41.2

Subtypes

LUMA

9/19.6

28/30.1

0.628^a, ^

4/16.0

33/28.9

0.010^c, ^

LUMB (HER2-NEG)

17/37.0

32/34.4

7/28.0

42/36.8

LUMB (HER2-POS)

10/21.7

16/17.2

4/16.0

22/19.3

HER2

2/4.3

6/17.2

1/4.0

7/6.1

Basal-like

6/13.0

4/4.3

9/36.0

1/0.9

UC

2/4.3

7/7.5

0/0

9/7.9

Grade

I

0/0

0/0

0.921^{a, #}

0/0

0/0

0.001^{a, #}

II

31/67.4

52/55.9

10/40.0

73/64.0

III

12/26.1

21/22.6

13/52.0

20/17.5

UC

3/6.5

20/21.5

2/8.0

21/18.4